Stephan Wullschleger

Title: The Innovations of Stephan Wullschleger

Introduction

Stephan Wullschleger is a notable inventor based in Urdorf, Switzerland. He has made significant contributions to the field of immunotherapy, particularly in the development of combination therapies targeting cancer.

Latest Patents

Wullschleger holds a patent for a groundbreaking invention titled "Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1." This patent focuses on the innovative combination of specific PD-1-targeted IL-2 variant immunocytokines with antibodies that bind to human PD-L1, aiming to enhance the efficacy of cancer treatments.

Career Highlights

Stephan Wullschleger is associated with Hoffmann-La Roche Inc., a leading global healthcare company. His work at Roche has positioned him at the forefront of cancer research and treatment development. He has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.

Collaborations

Wullschleger collaborates with esteemed colleagues, including Laura Codarri Deak and Douglas Hanahan. These partnerships enhance the research and development efforts in the field of immunotherapy, contributing to innovative solutions for cancer treatment.

Conclusion

Stephan Wullschleger's contributions to immunotherapy through his patent and work at Hoffmann-La Roche Inc. highlight his role as a key innovator in the fight against cancer. His research continues to pave the way for new therapeutic approaches that could significantly impact patient outcomes.